Exenatide efficacy and safety: A systematic review

Diabetic Medicine

Volumn 26, Issue 9, 2009, Pages 837-846

  Norris, S L ^a   Lee, N ^a   Thakurta, S ^a   Chan, B K S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Diabetes; Exenatide; Glycaemic control; Systematic review

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; PLACEBO; SULFONYLUREA;

CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VOMITING; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 69249195769     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02790.x     Document Type: Review

References (45)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 : S12 24.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999 281 : 2005 2012.
3. European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use. 2009. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/ byetta/byetta.htm Last accessed 8 May 2009.
4. Iltz JL, Baker DE, Setter SM, Campbell KR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006 28 : 652 665.
5. Center for Reviews and Dissemination. CRD Report 4, 2nd edn : Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews. 2001. Available at http://www.york.ac.uk/ inst/crd/report4.htm Last accessed 14 July 2009.
6. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Chichester : John Wiley & Sons Inc. 2000.
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003 327 : 557 560.
8. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 21 : 1539 1558.
9. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria : R Foundation for Statistical Computing, 2006.
10. Review Manager (RevMan). Computer Program. Version 4.2 for Windows. Oxford, UK : The Cochrane Collaboration, 2002.
11. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007 29 : 2333 2348.
12. 1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006 8 : 436 447.
13. Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin 2008 24 : 1395 1397.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 2635.
15. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007 29 : 139 153.
16. Davis S, Johns D, Maggs D, Northrup J, Xu H, Brodows R. Exploring the substitution of exenatide for insulin in patients with Type 2 diabetes treated with insulin in combination with oral antidiabetic agents. Diabetes Care 2007 30 : 2767 2772.
17. DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in meformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 1100. (Pubitemid 40616618)
18. Donekal S, Shomali ME. Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: comparison with clinical trials. Diabetes Res Clin Pract 2008 80 : e4 6.
19. Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008 24 : 639 644.
20. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005 143 : 559 569.
21. Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 : 1083 1091. (Pubitemid 40616617)
22. King AB, Wolfe G, Healy S. Clinical observations of exenatide treatment. Diabetes Care 2006 29 : 1984.
23. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008 24 : 275 286.
24. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007 50 : 259 267.
25. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007 9 : 317 326.
26. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006 8 : 419 428. (Pubitemid 44349234)
27. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006 22 : 483 491.
28. Secnik Boye K, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006 4 : 80.
29. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008 14 : 285 292.
30. Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007 146 : 477 485.
31. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008 358 : 1970 1971.
32. FDA. Byetta, Exenatide Safety Alerts. 2007. Available at http://www.fda.gov/medwatch/safety/2007/safety07.htm#Byetta Last accessed 10 November 2008.
33. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006 29 : 471.
34. FDA. Byetta-Patient Information. 2008. Available at http://www.fda.gov/ medwatch/safety/2008/Byetta-Jan2008-PI.pdf Last accessed 10 November 2008.
35. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007 298 : 194 206. (Pubitemid 47057766)
36. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007 23 : 1493 1507.
37. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991 44 : 1271 1278.
38. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001 20 : S21 35.
39. Home PD. Comment on: Nauck MA, Duran S, Kim D et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007 50 : 259 267. Diabetologia 2007; 50: 1561-1562; author reply 3-4.
40. Terrin N SC, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005 58 : 394 401.
41. Als-Nelson B, Chen W, Gluud C, Kjaergard L. Association of funding and conclusions in randomized drug trials. J Am Med Assoc 2003 290 : 921 928.
42. Lexchin J, Bero LA, Djulbejovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 2003 326 : 1167 1170.
43. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002 143 : 3152 3161.
44. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005 48 : 1339 1349.
45. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both B-cell replication and neogenesis resulting in increased B-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999 48 : 2270 2276.